Neurocognitive Function Following Therapy for Low-Grade Gliomas.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26050592.
- Also identified by DOI 10.1016/j.semradonc.2015.02.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Low-grade gliomas (LGGs) are a heterogenous group of primary brain neoplasms that most commonly occur in children and young adults, characterized by a slow, indolent course and overall favorable prognosis. Standard therapies used to treat LGGs have included surgical resection, radiotherapy, chemotherapy, or a combination thereof. Given the anticipated long survival and typical young age of patients with LGG, the long-term sequelae of therapy require special attention, especially as they affect neurocognitive function and quality of life. We review the complex interplay of baseline and treatment-related factors that perturb neurocognition as well as the effect of each treatment modality on altering neurocognitive outcomes in this patient population.
Medical subject headings
- Brain Neoplasms
- Cognition Disorders
- Glioma